Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
